Pfizer Inc's Corporate Customers have recorded an advance in their cost of revenue by 0.26 % in the 2 quarter 2026 year on year, sequentially costs of revenue grew by 3.33 %. During the corresponding time, Pfizer Inc recorded a revenue increase by 2.6 % year on year, sequentially revenue grew by 4.03 %. While revenue at the Pfizer Inc's corporate clients recorded rose by 2.81 % year on year, sequentially revenue grew by 2.26 %.
Pfizer Inc's Customers have recorded an advance in their cost of revenue by 0.26 % in the 2 quarter 2026 year on year, sequentially costs of revenue grew by 3.33 %, for the same period Pfizer Inc recorded revenue increase by 2.6 % year on year, sequentially revenue grew by 4.03 %.
Pfizer Inc's Comment on Sales, Marketing and Customers
The company markets its products to healthcare providers and patients in compliance with applicable laws and regulations. In the United States, it targets managed care organizations (MCOs) such as hospitals, integrated delivery systems, pharmacy benefit managers (PBMs), and health plans, as well as employers and government agencies that contract MCOs to provide health benefits. The company also conducts direct-to-consumer advertising in the U.S. and select international markets. It sponsors general advertising campaigns focused on disease awareness, prevention, wellness, public health issues, and patient assistance programs. The company participates in the TrumpRx.gov platform, enabling U.S. patients to purchase certain medicines at discounted prices. Its customer engagement strategy includes an omnichannel approach with both virtual and in-person interactions.
In a groundbreaking revelation, Pfizer Inc. and Astellas Pharma U.S. Inc. have unveiled significant findings from the Phase 3 EMBARK study, heralding a new era in the treatment landscape for men grappling with advanced prostate cancer. The trial results indicate that the combination therapy of XTANDI (enzalutamide) and leuprolide reduces the risk of death by an impressive 40% in men suffering from non-metastatic hormone-sensitive prostate cancer (nmHSPC), also referred to as nonmetastatic castration-sensitive prostate cancer (nmCSPC), compared to leuprolide alone.This promising advance is particularly pertinent for patients experiencing biochemical recurrence (BCR), wherein their cancer has returned despite ...
In a pivotal development in the ongoing battle against COVID-19, Pfizer Inc. and BioNTech SE have gained U.S. Food and Drug Administration (FDA) approval for their LP.8.1-adapted monovalent COVID-19 vaccine, COMIRNATY. Announced on August 27, 2025, this approval is significant as it extends vaccination eligibility to a critical demographic: adults aged 65 and older, along with individuals between the ages of 5 and 64 who possess underlying health conditions that elevate their risk for severe complications from the virus.This supplemental Biologics License Application (sBLA) approval represents a key milestone in the ongoing efforts to protect high-risk populations. With the global prevalence of COVID-19 cont...
Innovative Treatment Advantage: Vepdegestrant s Role in Redefining Progression-Free Survival in ESR1-Mutant Advanced Breast Cancer The pursuit of improving therapeutic outcomes for advanced breast cancer has reached a significant milestone with the results from the Phase 3 VERITAC2 clinical trial, heralding a promising new era in oncology. Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) have unveiled compelling data indicating that vepdegestrant, a novel oral selective estrogen receptor degrader (SERD), significantly enhances progression-free survival in patients with ESR1-mutant, ER+/HER2- advanced or metastatic breast cancer (MBC). This groundbreaking advancement was spotlighted at the American S...
Pfizer s Sasanlimab Combination Significantly Improves Event-Free Survival in High-Risk Non-Muscle Invasive Bladder Cancer Pfizer Inc. (NYSE: PFE), a leading global biopharmaceutical company headquartered in New York, has announced promising results from a pivotal Phase 3 CREST trial involving their investigational anti-PD1 monoclonal antibody (mAb), sasanlimab. This trial tested sasanlimab in combination with the standard of care Bacillus Calmette-Guerin (BCG) therapy as an induction treatment, with or without maintenance, in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC). According to the company s recent press release, the trial achieved its primary endpoint, demonstrating ...
In a notable advancement for oncology, the U.S. Food and Drug Administration (FDA) has approved Pfizer Inc.’s BRAFTOVI (encorafenib) in combination with cetuximab (ERBITUX) and the FOLFOX chemotherapy regimen for the treatment of metastatic colorectal cancer (mCRC) harboring the BRAF V600E mutation. This breakthrough approval is significant, but it arrives at a complex time for Pfizer as it navigates a corporate landscape characterized by fluctuating costs and revenues across its client sectors. Key Facts 1. FDA Approval of BRAFTOVI : - The approval marks a critical milestone, allowing the use of BRAFTOVI combined with ERBITUX and mFOLFOX6 as a first-line treatment for mCRC patients with the BRAF V600E ...
In a week marked by significant developments in pharmaceutical innovation and regulatory actions, Pfizer Inc. has garnered attention for two major announcements that highlight the dual nature of the biopharmaceutical landscape progress in hemophilia treatment coupled with compounded challenges in sickle cell disease management.On one hand, the U.S. Food and Drug Administration (FDA) has granted approval for HYMPAVZI (marstacimab-hncq), Pfizer s new therapy aimed at preventing bleeding episodes in individuals with hemophilia A and B. This therapy marks a pivotal moment for patients suffering from these conditions, representing the creative potential within biomedicine to alleviate the burden faced by countl...
In a significant move that has raised concerns among patients and healthcare providers, Pfizer Inc. (NYSE: PFE) announced its decision to voluntarily withdraw all lots of OXBRYTA (voxelotor) its treatment for sickle cell disease (SCD) from global markets. This withdrawal, which affects all markets where OXBRYTA is approved, follows a comprehensive analysis of clinical data indicating that the treatment s benefits no longer outweigh its associated risks. In addition to the withdrawal of OXBRYTA, Pfizer is halting all ongoing clinical trials and expanded access programs for voxelotor.The decision resonates deeply in a landscape where advancements in the treatment of chronic diseases are paramount. Sickle cell ...
The Latest Development in COVID-19 Vaccination: Pfizer and BioNTech s Omicron KP.2-adapted Vaccine Approved and Market Dynamics in 2024 In response to the evolving landscape of COVID-19 variants, Pfizer Inc. and BioNTech SE have made significant strides with the approval and authorization of their Omicron KP.2-adapted COVID-19 vaccine by the U.S. Food and Drug Administration (FDA). This article will delve into the implications of this approval, the current state of corporate climate surrounding Pfizer s products, and the socio-economic trends relevant to the pharmaceutical market. We will examine Pfizer s financial performance, its corporate client landscape, and the broader economic environment, including ...
In a significant development in the field of gene therapy, Pfizer Inc. (NYSE: PFE) recently announced the European Commission s conditional marketing authorization for DURVEQTIX (fidanacogene elaparvovec). This one-time gene therapy aims to treat adults with severe and moderately severe hemophilia B, offering a new lease on life for those grappling with congenital factor IX deficiency. The approval specifically targets patients who have no history of factor IX inhibitors and lack detectable antibodies to variant AAV serotype Rh74.DURVEQTIX has been meticulously designed to empower individuals by enabling their bodies to produce factor IX, an essential component for blood clotting, which they otherwise lack. ...
This article discusses the recent completion of the Phase 3 VALOR Lyme Disease Trial by Pfizer Inc. and Valneva SE, and its potential impact on the pharmaceutical industry. Additionally, it explores Pfizer Inc. s financial performance and its correlation with consumer spending and investments in the market. The findings from these two articles shed light on the current landscape of the industry and provide insights into the future developments and opportunities.Pfizer Inc. and Valneva SE recently announced the completion of the primary vaccination series of their Lyme disease vaccine candidate VLA15. The Phase 3 trial, named Vaccine Against Lyme for Outdoor Recreationists (VALOR), involved administering thre...
Pfizer Inc’s Comment on Sales, Marketing and Customers
The company markets its products to healthcare providers and patients in compliance with applicable laws and regulations. In the United States, it targets managed care organizations (MCOs) such as hospitals, integrated delivery systems, pharmacy benefit managers (PBMs), and health plans, as well as employers and government agencies that contract MCOs to provide health benefits. The company also conducts direct-to-consumer advertising in the U.S. and select international markets. It sponsors general advertising campaigns focused on disease awareness, prevention, wellness, public health issues, and patient assistance programs. The company participates in the TrumpRx.gov platform, enabling U.S. patients to purchase certain medicines at discounted prices. Its customer engagement strategy includes an omnichannel approach with both virtual and in-person interactions.
Sources:
Pfizer Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Pfizer Inc’s corporate clients.
For your research, we’ve provided 9 tables on Pfizer Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
14.53 %
2.65 % 